
Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Other EventsItem 8.01 Other Events.
On August30, 2018, Eagle Pharmaceuticals,Inc., or the Company, issued a press release announcing the completion of enrollment of the Company’s second clinical study to further evaluate the safety and efficacy of RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke, an investigational new indication for the product.
A copy of the full text of the press release referenced above is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
ExhibitNo. |
Description |
99.1 |
Press Release dated August30, 2018 |